Concepedia

Michael Hepperle

MH

Statistics

Publications

27

Citations

1.8K

H-Index

20

Active since

1993

Affiliations

University of Kansas(Current)

Millennium Engineering and Integration (United States)

Pfizer (United States)

National Cancer Institute

Michael Hepperle is an author at University of Kansas specializing in pharmacology, medicinal chemistry, and pharmacy.

Publications per year

1993–2011

27

Publications

27

Taxol®: science and applications.

M Suffness, Monroe E. Wall, H. R. Hartzell et al. · 1995 · 336 citations

Public Affairs, Pharmacokinetics, Pharmacology +3

Small molecule inhibitors of IkappaB kinase are selectively toxic for subgroups of diffuse large B-cell lymphoma defined by gene expression profiling.

Lloyd T. Lam, R. Eric Davis, Jackie Pierce et al. · PubMed · 2005 · 313 citations

Medicine, Oncology, Pharmacology +14

Small Molecule Inhibitors of IκB Kinase Are Selectively Toxic for Subgroups of Diffuse Large B-Cell Lymphoma Defined by Gene Expression Profiling

Lloyd T. Lam, R. Eric Davis, Jackie Pierce et al. · Clinical Cancer Research · 2005 · 223 citations · Full text

Medicine, Oncology, Pharmacology +11

A Selective Small Molecule IκB Kinase β Inhibitor Blocks Nuclear Factor κB-Mediated Inflammatory Responses in Human Fibroblast-Like Synoviocytes, Chondrocytes, and Mast Cells

Danyi Wen, Yuhua Nong, Jennifer G. Morgan et al. · Journal of Pharmacology and Experimental Therapeutics · 2006 · 113 citations

Medicine, Medicinal Chemistry, Pharmacology +17

IKKβ inhibition protects against bone and cartilage destruction in a rat model of rheumatoid arthritis

Lisa Schopf, Anneli Savinainen, Karen S. Anderson et al. · Arthritis & Rheumatism · 2006 · 80 citations

Medicine, Medicinal Chemistry, Pharmacology +15

1–5 of 27